ANNX
Annexon, Inc.
Price Chart
Latest Quote
$6.50
+0.95 (+17.12%)
Current Price
| Previous Close | $5.55 |
| Open | $5.87 |
| Day High | $6.51 |
| Day Low | $5.48 |
| Volume | 8,737,442 |
Stock Information
| Shares Outstanding | 163.84M |
| Total Debt | $25.43M |
| Cash Equivalents | $225.02M |
| Net Income | $-198.33M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $950.29M |
| EPS (TTM) | $-1.20 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $750.70M |
| Income | $-198.33M |
| Book/sh | $1.26 |
| Cash/sh | $1.37 |
| Employees | 93 |
Financial Ratios
| Quick Ratio | 6.26 |
| Current Ratio | 6.35 |
| Debt/Eq | 12.44 |
Returns & Margins
| ROA | -45.29% |
| ROE | -87.65% |
Ownership
| Insider Ownership | 0.49% |
| Institutional Ownership | 102.43% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.28 |
| P/B | 4.61 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $14.88 |
Technical Indicators
| SMA20 | $5.65 |
| SMA50 | $5.40 |
| SMA200 | $5.02 |
| RSI | 54.02 |
| ATR | 0.5089 |
| Shares Float | 129.36M |
| Short Float | 19.30% |
| Short Ratio | 7.16 |
| Volatility | 1.17 |
| Rel Volume | 0.59 |
Performance History
| Week | +0.00% |
| Month | +28.32% |
| Quarter | -8.37% |
| 6 Months | -13.17% |
| YTD | +23.67% |
| Year | +141.67% |
| 3 Years | +51.04% |
| 5 Years | -75.08% |
| 10 Years | -67.34% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $5.80 | 3,340,000 |
| 2026-07-16 | $5.89 | 7,711,300 |
| 2026-07-15 | $6.50 | 8,846,400 |
| 2026-07-14 | $5.55 | 5,555,900 |
| 2026-07-13 | $5.63 | 3,040,200 |
| 2026-07-10 | $5.80 | 2,736,900 |
| 2026-07-09 | $5.94 | 4,836,200 |
| 2026-07-08 | $5.96 | 7,549,000 |
| 2026-07-07 | $6.43 | 5,759,400 |
| 2026-07-06 | $5.96 | 6,778,900 |
| 2026-07-02 | $5.46 | 2,561,800 |
| 2026-07-01 | $5.55 | 4,919,700 |
| 2026-06-30 | $5.71 | 3,633,700 |
| 2026-06-29 | $5.57 | 8,568,200 |
| 2026-06-26 | $5.48 | 14,807,100 |
| 2026-06-25 | $5.15 | 3,830,600 |
| 2026-06-24 | $5.30 | 3,303,500 |
| 2026-06-23 | $5.28 | 5,852,100 |
| 2026-06-22 | $5.04 | 3,039,300 |
| 2026-06-18 | $4.90 | 7,342,600 |
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barrÊ syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
đ° Latest News
How Investors Are Reacting To Annexon (ANNX) Phase 3 Tanruprubart Win And Vonaprument Updates
Simply Wall St. âĸ 2026-07-16T23:17:41Z
Annexon Eyes âWin Seasonâ With Q4 Vision Trial Data, GBS Filings Ahead
MarketBeat âĸ 2026-06-09T13:06:41Z
Exploring 3 High Growth Tech Stocks in the US Market
Simply Wall St. âĸ 2026-06-09T11:38:22Z
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
MarketBeat âĸ 2026-06-04T07:07:07Z
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
MarketBeat âĸ 2026-05-14T08:05:47Z
Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential
Insider Monkey âĸ 2026-04-27T06:22:16Z
Annexon Biosciences (ANNX) Buy Rating Retained
Insider Monkey âĸ 2026-04-21T21:14:38Z
Annexon CEO Touts âWin Yearâ 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing
MarketBeat âĸ 2026-04-15T21:02:07Z
Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?
Zacks âĸ 2026-04-01T13:55:03Z
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Simply Wall St. âĸ 2026-04-01T10:59:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $216,407,000 | $154,073,000 | $143,723,000 | $145,599,000 |
| Net Non Operating Interest Income Expense | $9,717,000 | $15,873,000 | $9,486,000 | $3,652,000 |
| Operating Expense | $216,407,000 | $154,073,000 | $143,723,000 | $145,599,000 |
| General And Administrative Expense | $29,059,000 | $32,027,000 | $28,021,000 | $30,946,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-206,690,000 | $-138,200,000 | $-134,237,000 | $-141,947,000 |
| Net Interest Income | $9,717,000 | $15,873,000 | $9,486,000 | $3,652,000 |
| Interest Income | $9,717,000 | $15,873,000 | $9,486,000 | $3,652,000 |
| Normalized Income | $-206,690,000 | $-138,200,000 | $-134,237,000 | $-141,947,000 |
| Net Income From Continuing And Discontinued Operation | $-206,690,000 | $-138,200,000 | $-134,237,000 | $-141,947,000 |
| Total Operating Income As Reported | $-216,407,000 | $-154,073,000 | $-143,723,000 | $-145,599,000 |
| Net Income Common Stockholders | $-206,690,000 | $-138,200,000 | $-134,237,000 | $-141,947,000 |
| Net Income | $-206,690,000 | $-138,200,000 | $-134,237,000 | $-141,947,000 |
| Net Income Including Noncontrolling Interests | $-206,690,000 | $-138,200,000 | $-134,237,000 | $-141,947,000 |
| Net Income Continuous Operations | $-206,690,000 | $-138,200,000 | $-134,237,000 | $-141,947,000 |
| Pretax Income | $-206,690,000 | $-138,200,000 | $-134,237,000 | $-141,947,000 |
| Interest Income Non Operating | $9,717,000 | $15,873,000 | $9,486,000 | $3,652,000 |
| Operating Income | $-216,407,000 | $-154,073,000 | $-143,723,000 | $-145,599,000 |
| Depreciation Amortization Depletion Income Statement | $2,650,000 | $2,598,000 | $1,946,000 | $2,152,000 |
| Depreciation And Amortization In Income Statement | $2,650,000 | $2,598,000 | $1,946,000 | $2,152,000 |
| Depreciation Income Statement | $2,650,000 | $2,598,000 | $1,946,000 | $2,152,000 |
| Per Share | ||||
| Diluted EPS | $-1.34 | $-1.01 | $-1.77 | $-2.60 |
| Basic EPS | $-1.34 | $-1.01 | $-1.77 | $-2.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-213,757,000 | $-151,475,000 | $-141,575,000 | $-143,447,000 |
| Reconciled Depreciation | $2,166,000 | $2,150,000 | $2,148,000 | $2,106,000 |
| EBITDA (Bullshit earnings) | $-213,757,000 | $-151,475,000 | $-141,575,000 | $-143,447,000 |
| EBIT | $-216,407,000 | $-154,073,000 | $-143,723,000 | $-145,599,000 |
| Diluted Average Shares | $155,105,832 | $137,404,145 | $75,673,081 | $54,673,572 |
| Basic Average Shares | $155,105,832 | $137,404,145 | $75,673,081 | $54,673,572 |
| Diluted NI Availto Com Stockholders | $-206,690,000 | $-138,200,000 | $-134,237,000 | $-141,947,000 |
| Research And Development | $184,698,000 | $119,448,000 | $113,756,000 | $112,501,000 |
| Selling General And Administration | $29,059,000 | $32,027,000 | $28,021,000 | $30,946,000 |
| Other Gand A | $13,446,000 | $15,169,000 | $11,617,000 | $13,757,000 |
| Salaries And Wages | $15,613,000 | $16,858,000 | $16,404,000 | $17,189,000 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
Fetched: 2026-07-13
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $211,648,000 | $293,105,000 | $250,556,000 | $231,194,000 |
| Total Assets | $277,571,000 | $350,071,000 | $297,674,000 | $285,096,000 |
| Total Non Current Assets | $35,380,000 | $33,610,000 | $33,814,000 | $36,998,000 |
| Other Non Current Assets | $9,578,000 | $4,267,000 | $1,032,000 | $1,032,000 |
| Current Assets | $242,191,000 | $316,461,000 | $263,860,000 | $248,098,000 |
| Other Current Assets | $1,242,000 | $1,104,000 | $823,000 | $203,000 |
| Prepaid Assets | $2,604,000 | $3,340,000 | $3,321,000 | $5,238,000 |
| Cash Cash Equivalents And Short Term Investments | $238,345,000 | $312,017,000 | $259,716,000 | $242,657,000 |
| Cash And Cash Equivalents | $162,051,000 | $49,498,000 | $225,110,000 | $140,020,000 |
| Cash Equivalents | $160,038,000 | $46,847,000 | $216,622,000 | $139,450,000 |
| Cash Financial | $2,013,000 | $2,651,000 | $8,488,000 | $570,000 |
| Receivables | - | - | - | - |
| Debt | ||||
| Total Debt | $26,201,000 | $28,972,000 | $31,355,000 | $32,858,000 |
| Long Term Debt And Capital Lease Obligation | $23,293,000 | $26,454,000 | $29,190,000 | $31,542,000 |
| Current Debt And Capital Lease Obligation | $2,908,000 | $2,518,000 | $2,165,000 | $1,316,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $65,923,000 | $56,966,000 | $47,118,000 | $53,902,000 |
| Total Non Current Liabilities Net Minority Interest | $23,293,000 | $26,454,000 | $29,190,000 | $31,542,000 |
| Current Liabilities | $42,630,000 | $30,512,000 | $17,928,000 | $22,360,000 |
| Other Current Liabilities | $509,000 | $141,000 | $141,000 | $180,000 |
| Payables And Accrued Expenses | $31,696,000 | $22,020,000 | $10,015,000 | $15,565,000 |
| Payables | $14,931,000 | $10,426,000 | $5,487,000 | $7,416,000 |
| Accounts Payable | $14,931,000 | $10,426,000 | $5,487,000 | $7,416,000 |
| Non Current Deferred Liabilities | - | - | - | - |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $211,648,000 | $293,105,000 | $250,556,000 | $231,194,000 |
| Total Equity Gross Minority Interest | $211,648,000 | $293,105,000 | $250,556,000 | $231,194,000 |
| Stockholders Equity | $211,648,000 | $293,105,000 | $250,556,000 | $231,194,000 |
| Gains Losses Not Affecting Retained Earnings | $-29,000 | $10,000 | $-52,000 | $-372,000 |
| Other Equity Adjustments | $-29,000 | $10,000 | $-52,000 | $-372,000 |
| Retained Earnings | $-917,389,000 | $-710,699,000 | $-572,499,000 | $-438,262,000 |
| Other | ||||
| Ordinary Shares Number | $149,362,800 | $109,381,556 | $78,369,099 | $47,722,995 |
| Share Issued | $149,362,800 | $109,381,556 | $78,369,099 | $47,722,995 |
| Tangible Book Value | $211,648,000 | $293,105,000 | $250,556,000 | $231,194,000 |
| Invested Capital | $211,648,000 | $293,105,000 | $250,556,000 | $231,194,000 |
| Working Capital | $199,561,000 | $285,949,000 | $245,932,000 | $225,738,000 |
| Capital Lease Obligations | $26,201,000 | $28,972,000 | $31,355,000 | $32,858,000 |
| Total Capitalization | $211,648,000 | $293,105,000 | $250,556,000 | $231,194,000 |
| Additional Paid In Capital | $1,128,917,000 | $1,003,685,000 | $823,029,000 | $669,780,000 |
| Capital Stock | $149,000 | $109,000 | $78,000 | $48,000 |
| Common Stock | $149,000 | $109,000 | $78,000 | $48,000 |
| Long Term Capital Lease Obligation | $23,293,000 | $26,454,000 | $29,190,000 | $31,542,000 |
| Current Capital Lease Obligation | $2,908,000 | $2,518,000 | $2,165,000 | $1,316,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,517,000 | $5,833,000 | $5,607,000 | $5,299,000 |
| Current Accrued Expenses | $16,765,000 | $11,594,000 | $4,528,000 | $8,149,000 |
| Net PPE | $25,802,000 | $29,343,000 | $32,782,000 | $35,966,000 |
| Accumulated Depreciation | $-9,345,000 | $-7,179,000 | $-5,029,000 | $-2,883,000 |
| Gross PPE | $35,147,000 | $36,522,000 | $37,811,000 | $38,849,000 |
| Leases | $17,262,000 | $17,254,000 | $17,245,000 | $17,231,000 |
| Other Properties | $17,063,000 | $18,543,000 | $19,841,000 | $20,892,000 |
| Machinery Furniture Equipment | $822,000 | $725,000 | $725,000 | $726,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $76,294,000 | $262,519,000 | $34,606,000 | $102,637,000 |
| Preferred Stock | - | - | - | - |
Fetched: 2026-07-13
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-186,493,000 | $-118,021,000 | $-121,335,000 | $-122,835,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-186,356,000 | $-118,006,000 | $-121,142,000 | $-116,309,000 |
| Cash Flow From Continuing Operating Activities | $-186,356,000 | $-118,006,000 | $-121,142,000 | $-116,309,000 |
| Investing Activities | ||||
| Capital Expenditure | $-137,000 | $-15,000 | $-193,000 | $-6,526,000 |
| Investing Cash Flow | $190,052,000 | $-218,797,000 | $70,703,000 | $58,443,000 |
| Cash Flow From Continuing Investing Activities | $190,052,000 | $-218,797,000 | $70,703,000 | $58,443,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $109,559,000 | $161,871,000 | $135,510,000 | $130,476,000 |
| Financing Cash Flow | $108,855,000 | $161,206,000 | $135,524,000 | $122,908,000 |
| Cash Flow From Continuing Financing Activities | $108,855,000 | $161,206,000 | $135,524,000 | $122,908,000 |
| Net Other Financing Charges | $-1,619,000 | $-2,259,000 | $-555,000 | $-7,988,000 |
| Net Common Stock Issuance | $109,559,000 | $161,871,000 | $135,510,000 | $130,476,000 |
| Common Stock Issuance | $109,559,000 | $161,871,000 | $135,510,000 | $130,476,000 |
| Repurchase Of Capital Stock | - | - | - | - |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Income Tax Paid Supplemental Data | $5,065,000 | $4,893,000 | $4,728,000 | - |
| End Cash Position | $163,083,000 | $50,530,000 | $226,142,000 | $141,052,000 |
| Beginning Cash Position | $50,530,000 | $226,142,000 | $141,052,000 | $76,009,000 |
| Effect Of Exchange Rate Changes | $2,000 | $-15,000 | $5,000 | $1,000 |
| Changes In Cash | $112,551,000 | $-175,597,000 | $85,085,000 | $65,042,000 |
| Proceeds From Stock Option Exercised | $915,000 | $1,594,000 | $569,000 | $420,000 |
| Net Investment Purchase And Sale | $190,189,000 | $-218,782,000 | $70,896,000 | $64,969,000 |
| Sale Of Investment | $402,400,000 | $365,150,000 | $178,984,000 | $178,166,000 |
| Purchase Of Investment | $-212,211,000 | $-583,932,000 | $-108,088,000 | $-113,197,000 |
| Net PPE Purchase And Sale | $-137,000 | $-15,000 | $-193,000 | $-6,526,000 |
| Purchase Of PPE | $-137,000 | $-15,000 | $-193,000 | $-6,526,000 |
| Change In Working Capital | $4,230,000 | $6,361,000 | $-5,805,000 | $3,738,000 |
| Change In Other Current Liabilities | $-2,771,000 | $-2,383,000 | $-1,503,000 | $-1,690,000 |
| Change In Other Current Assets | $-5,311,000 | $-3,184,000 | $0 | - |
| Change In Payables And Accrued Expense | $11,714,000 | $12,228,000 | $-5,654,000 | $5,891,000 |
| Change In Accrued Expense | $7,223,000 | $7,292,000 | $-3,577,000 | $6,178,000 |
| Change In Payable | $4,491,000 | $4,936,000 | $-2,077,000 | $-287,000 |
| Change In Account Payable | $4,491,000 | $4,936,000 | $-2,077,000 | $-287,000 |
| Change In Prepaid Assets | $598,000 | $-300,000 | $1,352,000 | $-463,000 |
| Other Non Cash Items | $1,520,000 | $1,304,000 | $1,119,000 | $1,205,000 |
| Stock Based Compensation | $16,423,000 | $19,433,000 | $18,183,000 | $18,516,000 |
| Amortization Of Securities | $-4,005,000 | $-9,054,000 | $-2,550,000 | $73,000 |
| Depreciation Amortization Depletion | $2,166,000 | $2,150,000 | $2,148,000 | $2,106,000 |
| Depreciation And Amortization | $2,166,000 | $2,150,000 | $2,148,000 | $2,106,000 |
| Net Income From Continuing Operations | $-206,690,000 | $-138,200,000 | $-134,237,000 | $-141,947,000 |
| Repayment Of Debt | - | - | - | - |
| Issuance Of Debt | - | - | - | - |
| Preferred Stock Payments | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-07-13